Shionogi Pharmaceuticals Applies For Approval Of ARB Irbetan And Compounding Agent
This article was originally published in PharmAsia News
Executive Summary
Shionogi Pharmaceuticals announced July 30 it applied for the approval of the high blood pressure drug Irbetan (irbesartan) and the diuretic Fluitran (trichlormethiazide) in Japan.